Future perspectives focus on optimizing dosing schedules to manage hematologic toxicities, utilizing additional biomarkers (beyond TP53 mutational status) for better patient stratification, and expanding their use to new indications like breast cancer, non-small-cell lung cancer (NSCLC), and gliomas, all harboring wild-type TP53 status. This evidence concerns the gene TP53 and glioma.